$SCL

Daily NZX update, Wednesday, May 27, 2026

The NZX50 rose 0.7% to extend gains to 3.1% over five days and 3.1% for the month (still down 2.0% over six months; up 4.6% YoY). Kathmandu Holdings jumped 14% and KMD reported Q3 FY26 sales +5.2% YoY and gross margin 58.2% (+258 bps). Vista Group gained 4% on a new five-year Cinemex deal; PaySauce revenue rose 3% to $9.2m.

Original reporting
Published May 27, 2026, 7:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Daily NZX update, Wednesday, May 27, 2026 — source image
Decision brief

The 30-second read

$SCLNeutralHigh
01

Why it matters

Stock-level catalysts are the primary drivers: VGL’s multi-year Cinemex platform transition, KMD’s Q3 margin/sales momentum plus a shareholder-return review, PYS’s growth with investment drag and funding, and SCL’s guidance reaffirmation amid operational disruptions.

02

Market read

The article is likely to influence short-horizon trading in VGL, KMD, PYS, and SCL due to quantified operational updates, guidance, and a large multi-year customer agreement.

03

What to watch

For SCL, receivership-related disruption (Esro Vlees BV) and weather-driven packout variability may dominate near-term sentiment more than the guidance headline.

Relevance 9/10Timing: Multiple company-specific announcements (contract, quarterly update, FY results, guidance) likely drive same-day-to-1-week repricing.

Background

This is a daily NZX market wrap summarizing index performance, top movers, ETF moves, and several company announcements (contract, quarterly update, FY26 trading update/guidance, and capital raise).

Company-level read

Ticker impact

$SCLNeutralMedium confidence
Context

Scales reiterated FY26 guidance for Underlying NPAT of $50m-$55m and cited trading strength despite disruption from the Iran war and protein division issues.

Expected impact

Stabilizing bias from guidance, with limited upside unless protein/receivership impacts improve faster than expected.

Evidence & confidence

The article reiterates a numeric guidance range but leaves uncertainty around receivership disruption and weather/packout impacts.

Market effects

Cinema software/platform wins (VGL) and payroll platform scaling (PYS) reinforce demand for recurring SaaS-like services, while consumer retail momentum (KMD) highlights resilience in branded apparel.

NZX large-caps moving higher alongside company updates suggests NZ investor risk appetite remains constructive.

Cinemex’s US-to-Mexico rollout (VGL) and PaySauce’s Australian expansion (PYS) tie NZ-listed growth to regional operating footprints beyond New Zealand.

Counterpoint

KMD’s business review and PYS’s investment-led earnings pressure could mean near-term optimism is ahead of measurable shareholder-return outcomes or profitability inflection.

Key entities

  • Vista Group

    Announced a five-year agreement with Cinemex to transition Mexico operations back to Vista’s platform during 2026.

  • KMD Brands

    Reported Q3 FY26 momentum with sales growth and gross margin expansion; launched a comprehensive business review.

  • PaySauce

    Reported FY26 NZ payroll growth, advanced Australian expansion, and completed a $5 mln capital raise.

  • Scales Corporation

    Reiterated FY26 Underlying NPAT guidance and discussed trading performance and disruption impacts.

Related articles

$SCLMed

Stepan Company Q2 2026 Earnings Call Summary

Strategic Performance Drivers Adjusted EBITDA growth of 45% was driven by a combination of 6% organic volume growth, disciplined pricing execution, and ramping productivity gains. Surfactant performance benefited from broad-based demand across all end markets, specifically led by industrial cleaning, laundry, and oil field sectors. Margin recovery was achieved through the rigorous application of contractual pass-through mechanisms and pricing actions to offset fluctuating raw material costs.

$SCLMedAI 8/10

Stepan Reports Second Quarter 2026 Results

Stepan (NYSE: SCL) reported Q2 2026 net income of $22.9M, up 102% year over year, and adjusted net income of $27.1M, up 126%. Adjusted EBITDA rose 45% to $74.4M. Net sales increased 15% to $684.1M, with organic volume up 6%. Free cash flow was -$15.0M due to working capital. The company plans to cut about 100 salaried roles under Project Catalyst and expects full-year restructuring charges of $75.0M-$80.0M.

$SCLMed

STEPAN CO (SCL): Results of Operations and Financial Condition

STEPAN CO (SCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d139905dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stepan Reports Second Quarter 2026 Results Northbrook, Illinois, July 29, 2026 — Stepan Company (NYSE: SCL) today reported: Second Quarter 2026 Highlights • Reported net income was $22.9 million, up 102% versus the prior ye

$RYMMedAI 8/10

Daily NZX update, Wednesday, June 3, 2026

NZX50 was down 0.3% at 3:00pm, though up 0.4% over five sessions and 6.5% over 12 months. Gentrack Group led gainers (+4%), while Vista Group fell the most (-3%). Ebos (-3%) and A2 Milk (-1%) also declined. Ryman Healthcare is considering new six-year secured bonds; Scales Corp declared a 12.5c FY2025 final dividend; Pacific Edge raised NZ$36.1m at NZ$0.17/share.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.